

1 **Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media**  
2 **with otorrhea among Bangladeshi children**

3 Hakka Naziat<sup>1,2</sup>, Md Hafizur Rahman<sup>1</sup>, Rajib C Das<sup>1</sup>, Maksuda Islam<sup>1</sup>, Shampa Saha<sup>1</sup>, Md.

4 Manzoor Hussain<sup>3</sup>, Asif Sattar<sup>3</sup>, Mohammad J Uddin<sup>1</sup>, Md. Jahangir Alam<sup>4</sup>, Cynthia G.

5 Whitney<sup>5</sup>, Senjuti Saha<sup>1</sup>, Yogesh Hooda<sup>1, \*</sup>, Samir K Saha<sup>1,2, \*</sup>

6

7 1. Child Health Research Foundation, Dhaka, Bangladesh

8 2. Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh

9 3. Department of Ear, Nose and Throat, Bangladesh Shishu Hospital and Institute, Dhaka,

10 Bangladesh

11 4. Department of Pediatrics, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh

12 5. Rollins School of Public Health, Emory University, Atlanta, USA

13

14 **\* Corresponding author:**

15 Samir K. Saha PhD FRCPATH FAAM

16 [samir@chrfd.org](mailto:samir@chrfd.org)

17 Child Health Research Foundation, SEL Huq Skypark, 23/2 Khilji Road, Mohammadpur, Dhaka,

18 1207

19 AND

20 Yogesh Hooda PhD

21 [yhooda@chrfd.org](mailto:yhooda@chrfd.org)

22 Child Health Research Foundation, SEL Huq Skypark, 23/2 Khilji Road, Mohammadpur, Dhaka,

23 1207

24

25 **Keywords:** *Streptococcus pneumoniae*, pneumococcal conjugate vaccines, otitis media,

26 Bangladesh

27 **ABSTRACT**

28 In 2015, Bangladesh introduced the ten-valent pneumococcal conjugate vaccine (PCV10). This  
29 study evaluates the impact of PCV10 on pneumococcal otitis media (OM), a prevalent middle  
30 ear infection amongst children in low-and-middle income countries, including Bangladesh. We  
31 analyzed ear swabs from OM cases with otorrhea collected at the largest pediatric hospital in  
32 Dhaka, Bangladesh from April 2014 to March 2019. The study involved identifying pathogens  
33 and conducting pneumococcal serotyping using the Quellung reaction.

34

35 Four years post PCV10 introduction, the rate of detection of pneumococcus among otorrhea  
36 cases decreased from 18.4% (164/892) in 2014-15 to 15.6% (581/3735) in 2018-19, reflecting a  
37 15.4% reduction. Notably, vaccine serotypes (VTs) demonstrated a significant decline  
38 throughout the post-PCV years, with a 44.1% reduction compared to the pre-PCV period.  
39 Specific VTs like 14, 6B and 19F exhibited significant reductions of 60.2%, 57.5% and 42.9%  
40 respectively. Conversely, non-vaccine serotypes (NVTs) showed non-significant increase of  
41 8.6%; specifically serotype 35B showed a 70.1% increase. Administration of two or three doses  
42 of PCV10 provided 84.4% protection against OM cases caused by serotypes covered by PCV10.

43

44 This is the first report from South Asia assessing PCV's impact on pneumococcal OM. It  
45 demonstrates a 15.4% reduction in pneumococcal isolation over four years and over 80%  
46 efficacy of PCV10 in preventing vaccine type pneumococcal OM cases. While some vaccine  
47 serotypes decreased significantly, the impact of PCV10 on overall pneumococcal OM cases was  
48 dampened by increasing isolation of non-vaccine serotypes.

## 49 INTRODUCTION

50 *Streptococcus pneumoniae*, or pneumococcus, is a significant bacterial pathogen responsible for  
51 a range of pediatric infections worldwide, including meningitis, sepsis, pneumonia and otorrhea  
52 [1,2]. Given the considerable global burden of pneumococcus-associated morbidity and  
53 mortality, the World Health Organization has recommended the inclusion of pneumococcal  
54 conjugate vaccine (PCV) in the routine immunization programs of all countries and assessment  
55 of its impact on pneumonia, other invasive diseases, and otitis media (OM) [3,4]. In March 2015,  
56 Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10), targeting 10  
57 serotypes: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F [5]. In addition, PCV10 was also  
58 anticipated to provide cross-protection against 6A due to immunologic similarities with vaccine  
59 serotype 6B [6–8]. Bangladesh has successfully achieved high coverage (99.2% coverage for  $\geq 2$   
60 doses) of PCV10 across the country [9], and recent studies have reported a decline in severe  
61 radiologically confirmed pneumonia amongst children under the age of five years at two sites in  
62 rural Bangladesh – Mirzapur [5] and Sylhet [10]. Nevertheless, the broader impact of PCV10 on  
63 other pneumococcal diseases remain to be assessed.

64  
65 Otitis media is among the most common bacterial infections diagnosed in children globally, with  
66 peak incidences typically within the first two years of life [11,12]. OM can range from  
67 asymptomatic cases, which usually resolve or are treated without complications, to more severe  
68 forms such as recurrent, nonresponsive, dry perforation, spontaneously draining, and chronic  
69 suppurative OM [13]. In Bangladesh, pneumococcus is a principal cause of OM, accounting for  
70 18% of all OM cases [14]. PCV10 and PCV10+6A serotypes accounted for 8% and 9% of all  
71 OM cases and 46% and 49% of pneumococcus-positive cases, respectively, and these serotypes

72 exhibited a higher likelihood to be non-susceptible to at least one antibiotic (erythromycin and/or  
73 trimethoprim-sulfamethoxazole) than nonvaccine serotypes (91% vs. 77%). A recent Cochrane  
74 review including 15 publications from 11 trials reported that administration of the licensed  
75 seven-valent pneumococcal conjugate vaccine (PCV7) and ten-valent PCV (PCV10) during early  
76 infancy substantially reduced the relative risk of pneumococcal OM [15].

77

78 To assess the impact of PCV10 on pneumococcal OM, our research group conducted a study to  
79 identify and characterize bacterial pathogens of OM in the ear, nose, and throat (ENT) outpatient  
80 department of Bangladesh Shishu Hospital and Institute from 2014 to 2019, spanning one year  
81 prior to PCV10 introduction and four years following the PCV10 introduction. The study aimed  
82 to determine a) the impact of PCV10 on percentage of OM cases that were pneumococcus-  
83 positive, b) changes in serotype distribution amongst pneumococcal OM cases, c) variations in  
84 the age of infection and duration of ear discharge, and d) the antimicrobial susceptibility of  
85 pneumococcus isolated from OM cases.

86

## 87 **METHODS**

88 The methodology employed in this study adhered strictly to those outlined in our previously  
89 published baseline study [14], with no modifications. This consistency ensured the comparability  
90 of results across both study periods. Details are provided below.

91

### 92 **Study site and population**

93 The study was conducted at Bangladesh Shishu Hospital and Institute (BSHI, formerly known as  
94 Dhaka Shishu Hospital or DSH), the largest pediatric hospital in Bangladesh, which serves

95 children from 0 to 18 years. This hospital has a dedicated out-patient department (OPD) for the  
96 management of all cases seeking care for ear, nose, and throat (ENT) conditions.

97

### 98 **Case identification and enrollment criteria**

99 Children presenting with symptoms suggestive of otitis media (OM) were identified by a study  
100 physician based on World Health Organization-recommended clinical criteria and otoscopic  
101 examinations [16,17]. The inclusion criteria for OM cases were: (1) acute onset of one or more  
102 sign/symptoms of infection such as fever, earache, ear tugging or irritability, and (2) middle ear  
103 inflammation with/without middle ear effusion or spontaneous discharge (otorrhea). From  
104 enrolled children with/without otorrhea (not caused by otitis externa), data on sex, age, duration  
105 of discharge, and antibiotic use within the previous seven days were recorded. Informed consent  
106 was obtained from caregivers for children with otorrhea to collect specimens.

107

### 108 **Specimen collection**

109 Specimens were collected from children presenting with otorrhea by trained research assistants.  
110 The external auditory canal was swabbed after the removal of any debris, using a flocced swab,  
111 and placed into a tube containing STGG medium (2% skim milk, 3% tryptone, 10% glycerol and  
112 0.5% glucose). Each specimen was cultured within three hours in the laboratory and examined  
113 for the presence of bacterial pathogens.

114

### 115 **Laboratory methods**

116 All specimens were cultured on blood agar with and without gentamicin (in 5% CO<sub>2</sub>  
117 environment), chocolate agar with bacitracin and MacConkey agar [17]. Growth on these

118 selective media were examined for the presence of *Haemophilus influenzae*, *S. pneumoniae*, and  
119 other bacterial pathogens, such as *Staphylococcus aureus*, *Moraxella catarrhalis*, *Pseudomonas*  
120 *spp.*

121  
122 Pneumococcal isolates were serotyped using the Quellung reaction [18]. Antibiotic susceptibility  
123 testing was conducted using the disc diffusion method adhering to the latest Clinical and  
124 Laboratory Standards Institute (CLSI) guidelines [19]. Antibiotics tested included penicillin (1  
125 µg oxacillin disc), trimethoprim-sulfamethoxazole (1/19, 25 µg disc), chloramphenicol (30 µg  
126 disc), erythromycin (15 µg disc) and ciprofloxacin (5 µg disc). Non-susceptible pneumococcal  
127 isolates were further tested using the E-test to determine minimum inhibitory concentrations.

128

### 129 **Indirect cohort analysis**

130 Vaccine effectiveness was assessed by comparing the vaccination status of children with  
131 vaccine-type OM (VT-OM) and non-vaccine-type OM (NVT-OM). This analysis assumes that  
132 vaccination does not influence the risk for non-vaccine-type disease among vaccinated  
133 individuals. A recent study has shown that results derived from the indirect cohort method were  
134 comparable to that of a standard case-control study [20,5], which is complex and difficult to  
135 implement. VT-OM was defined as OM cases in which PCV10 serotypes or 6A were identified,  
136 all other serotypes were considered NVT. All pneumococcal OM cases from April 2015 through  
137 March 2019 were used for this analysis. Based on the immunization status verified by the  
138 vaccination card or the caregiver's verbal confirmation (in cases where the card was not available  
139 or lost), children were classified into two groups: vaccinated and unvaccinated. The unvaccinated  
140 cohort included verbally confirmed non-vaccinated children and 2 - <24-month-old children who

141 were not age-eligible for PCV at the time of the initial pneumococcal vaccination program (21st  
142 March 2015). As Bangladesh's EPI did not have catch-up campaigns and only children aged 6  
143 weeks were eligible for vaccine introduction, this strategy led to an increase of vaccine eligible  
144 children gradually with time. To identify vaccine eligible children, we back calculated the  
145 birthdate of children and considered those born on 7th February 2015 or later as eligible to  
146 receive the 1st dose of pneumococcal vaccine at 6 weeks of age. Children who sought medical  
147 care two weeks or more after receiving an initial dose were considered vaccinated. Any child  
148 who came to the hospital within 14 days of receiving the 1st dose of PCV10 vaccine was  
149 considered non-vaccinated. Children who received two or three doses of PCV10 were considered  
150 individually for calculating vaccine impact, using children with no doses were used the  
151 comparison group. We calculated the odds ratio of receipt of PCV10 dose among children who  
152 had vaccine-type (PCV10) OM versus non-vaccine-type OM and used logistic regression to  
153 estimate vaccine effectiveness, calculated as: Vaccine effectiveness = (1-odds ratio for PCV10  
154 vaccination) x 100%.

155

### 156 **Statistical data analysis**

157 Data analyses were conducted using STATA 14.0 (Stata Corp LP, College Station, TX).

158 Epidemiological data were analyzed to elucidate the serotype distribution amongst

159 pneumococcal OM cases, duration of ear discharge, and antibiotic susceptibility profiles of *S.*

160 *pneumoniae* isolates. Common contaminants (e.g., *Bacillus spp.*, *Staphylococcus spp.* etc.) were

161 excluded.

162

### 163 **Ethical clearance**



164 This surveillance protocol was approved by the Institutional Review Board of Bangladesh  
165 Institute of Child Health at BSHI. Specimens were collected as part of routine patient care.

166

## 167 RESULTS

168 From April 2014 to March 2019, a total of 5,040 OM cases were identified, with 4,279 (93.8%)  
169 classified as otorrhea cases (Figure 1, Table 1). Ear swabs were successfully collected from  
170 4,626 (97.8%) of these cases. A pathogen could be identified in 2,181 of the 4,626 samples  
171 (47.1%; Supplemental Table 1). *H. influenzae* was the most frequently detected pathogen  
172 (782/2,181; 35.8%), followed by *S. pneumoniae* (581/2,181; 26.6%), *S. aureus* (514/2,181;  
173 23.6%) and *Pseudomonas spp.* (365/2,181; 16.7%). The trends in isolation of all detected causes  
174 of OM cases are shown in Figure 2. In 554 out of the 2,181 culture-positive cases (25.4%),  
175 multiple organisms were detected.


176

177 **Table 1:** Total, PCV10-type and non-PCV10-type *S. pneumoniae* obtained from OM cases in  
178 this study.

	April 2014- March 2015	April 2015- March 2016	April 2016- March 2017	April 2017- March 2018	April 2018- March 2019	Total post- PCV
<b>OM episodes recorded</b>	1111	1089	979	909	952	3929
<b>Episodes with otorrhea</b>	981	1061	963	840	884	3748
<b>Specimens collected</b>	891	1054	960	839	882	3735
<b>Total <i>S. pneumoniae</i> detected</b>	164	167	148	153	113	581
<b>PCV10-type <i>S. pneumoniae</i> detected</b>	76	72	50	28	28	178
<b>Non-PCV10 type <i>S.</i></b>	88	95	98	125	85	403

*pneumoniae* detected

179




180

181 **Figure 1:** Study design highlighting the number of yearly *S. pneumoniae* isolates collected  
182 during the baseline (Pre-PCV, April 2014-March 2015) and present study period (Post-PCV,  
183 April 2015- March 2019).

184

185 **Trends in number and serotype distribution of pneumococcal positive otorrhea cases**

186 From April 2014 to March 2015, 164 pneumococcal OM cases were identified. This number  
187 reduced to 113 by April 2018 to March 2019. Over the four years following the introduction of  
188 PCV10, the pneumococcal positivity among otorrhea cases decreased from 18.4% (164/892) to  
189 15.6% (581/3,735) [15.4% reduction (95% CI: -1.2-28.9%);  $p=0.04$ ] (Figure 3). The detection  
190 rate for *Haemophilus influenzae*, *Staphylococcus aureus* and *Pseudomonas spp* was not affected  
191 (Figure 2).



192  
193 **Figure 2:** Trends in isolation of all cause OM, and OM caused by *H. influenzae*, *S. pneumoniae*,  
194 *S. aureus*, *Pseudomonas spp.*

195  
196 Vaccine serotypes displayed a declining trend over the post-PCV year, resulting in a 44.1% (95%  
197 CI: 25.8 - 57.5%,  $p<0.001$ ) reduction compared to the pre-PCV period (Figure 3). Notably VTs  
198 like 14, 6B and 19F showed significant reductions of 60.2% (95% CI: 10.7% - 81.7%;  $p=0.009$ ),  
199 57.5% (95% CI: -9.01-82.3%;  $p=0.026$ ) and 42.9% (95% CI: 2.6-65.5%;  $p=0.015$ ), respectively

200 (Figure 4A). No protection was seen for Serotype 1 (35.6%, 95% CI: -85.7%-83.7%; p=0.215).

201 While the percentage of OM cases attributable to 6A declined, this change was not statistically

202 significant (10.4% reduction, 95% CI: -270.7% - 71.5%; p=0.405).

203

204 Non-PCV10 serotypes showed a slight increase although not significant (8.6% increase, 95% CI:


205 -15.4-28.2%, p=0.225), particularly 35B, which exhibited a 70.1% increase (95% CI: -18.6% -

206 96.6%; p=0.04) (Figure 3, Sup Figure 1). Certain serotypes absent in the pre-PCV period were

207 notably present in substantial numbers during the post-PCV period, including serotype 17F


208 (N=13), 12F (N=9), and 18A (N=7) (Sup Figure 1).

209



210

211 **Figure 3:** Percent of OM cases attributable to *S. pneumoniae* at Bangladesh Shishu Hospital and  
 212 Institute in Dhaka, Bangladesh from April 2014 to March 2019. Trends of all *S. pneumoniae*  
 213 (green), PCV10-type *S. pneumoniae* (VT, blue) and non-PCV10-type *S. pneumoniae* (NVT, red)  
 214 isolated from OM cases is shown.  
 215  
 216



217

218 **Figure 4:** Trends in the proportion of OM cases attributable to vaccine-type *S. pneumoniae* from  
219 April 2014 to March 2019. A) The yearly trends of percentage of VT-OM cases caused by  
220 different VT pneumococcal serotypes included in PCV7 (pink), PCV10-GSK (dark blue),  
221 PCV10-SII (purple), PCV13 (sky blue), PCV15 (yellow) and PCV20 (green) are shown. B) The  
222 estimated coverage of different PCV vaccines in the pre-PCV and post-PCV period.

223

224 Based on our data, the estimated serotype coverage of different PCVs for OM cases amongst  
225 Bangladeshi infants during the pre-PCV period (2014-2015) was 37.8% for PCV7, 46.3% for  
226 PCV10<sub>GSK</sub> 62.2% for PCV10<sub>SII</sub>, 72.6% for PCV13, 72.6 % for PCV15 and 79.3% for PCV20.  
227 Four years after the introduction of PCV10 (2018-2019), the estimated serotype coverage  
228 changed to 23.8% for PCV7, 30.6% for PCV10<sub>GSK</sub>, 41.7% for PCV10<sub>SII</sub>, 53.5% for PCV13,  
229 54.4% for PCV15 and 64.5% for PCV20 (Figure 4B).

230


### 231 **Age and ear discharge duration**

232 The median age of a child with pneumococcal OM was 10.0 months (95%CI: 9.0-13.0) in the  
233 pre-PCV period and 13.0 months (95%CI, 11.0-14.0) in the post-PCV period (Sup Figure 2). The  
234 median ear discharge duration was 5 days (95% CI: 5-6) in pre-PCV period and 5 days (95% CI:  
235 4-5) in the post-PCV period (Sup Figure 3). Trend analysis found no statistical difference in the  
236 median age or ear discharge duration throughout the study period.

237

### 238 **Trends of antibiotic susceptibility of pneumococcus**

239 A large percentage of pneumococcal isolates were resistant to cotrimoxazole (58%) and  
240 erythromycin (72%), while low rates of resistance were observed for penicillin (0.95%),  
241 chloramphenicol (5.5%) and ciprofloxacin (6.9%). No statistical difference in trends was  
242 observed for the five antibiotics tested over the study period (Figure 4).



243

244 **Figure 4:** Trends in antimicrobial susceptibility of *S. pneumoniae* isolates against five antibiotics  
245 (penicillin, chloramphenicol, cotrimoxazole, erythromycin and ciprofloxacin the during the study  
246 period. The proportion of isolates that were resistant to each drug is shown.

247

#### 248 **PCV10 effectiveness calculation**

249 Between March 21, 2015, and March 31, 2019, 581 cases of pneumococcal OM were identified,

250 with 323 children being eligible for PCV10 vaccination based on their age. Among these, 178

251 (30.6%) were of vaccine-type (VT) and 403 (69.4%) were non-vaccine-type (NVT). Of the

252 vaccinated children (n=307), 55 had VT OM, and 252 had NVT OM. Among the unvaccinated

253 (n=274), 123 had VT OM, and 151 had NVT OM. The median age of vaccinated children and

254 unvaccinated children were 7.0 and 33.5 months, respectively. The effectiveness of the 1<sup>st</sup>

255 PCV10 dose was 83.5% (95% CI: 29.4% - 96.2%; p-value =0.011), 2<sup>nd</sup> PCV10 dose was 82.1%

256 (95% CI: 42.2% - 94.5%; p-value =0.003) and 3<sup>rd</sup> PCV10 dose was 84.3% (95% CI: 57.1% -



257 94.5%; p-value<0.001) (Table 2). Two or three PCV10 doses provided 84.4% (95% CI: 57.1% –  
258 94.3%; p-value <0.001) protection against VT OM (Table 2).

259

260 **Table 2:** Indirect cohort analysis for PCV10 effectiveness calculation.

<b>PCV doses</b>	<b>VT vaccinated case/Total</b>	<b>NVT vaccinated case/Total</b>	<b>vaccine effectiveness (95% CI)</b>	<b>p-value</b>
<b>1<sup>st</sup> dose</b>	4/14 (28.6%)	17/24 (70.8%)	83.5% (29.4%, 96.2%)	0.0106
<b>2<sup>nd</sup> dose</b>	11/21 (52.4%)	43/50 (86.%)	82.1% (42.2%, 94.5%)	0.0034
<b>3<sup>rd</sup> dose</b>	46/56 (82.1%)	212/219 (96.8%)	84.8% (57.9, 94.5%)	0.0003
<b>1<sup>st</sup>+2<sup>nd</sup> dose</b>	15/25 (60%)	60/67 (89.6%)	82.5% (46.4%, 94.3%)	0.0020
<b>2<sup>nd</sup>+3<sup>rd</sup> dose</b>	57/67 (85.1%)	255/262 (97.3%)	84.4% (57.1%, 94.3%)	0.0003

261

## 262 **DISCUSSION**

263 Otitis media continues to be one of the most prevalent pediatric infections in Bangladesh, and a  
264 common cause of antibiotic prescriptions. This study, the largest case series of OM from  
265 Bangladesh - a country with a population of 170 million, examined the impact of PCV10 on  
266 pneumococcal OM. Specifically, it assessed changes in serotype distribution, duration of ear  
267 discharge, age distribution, and antibiotic susceptibility, allowing for the calculation of PCV10's  
268 effectiveness in preventing OM cases cause by vaccine serotypes. To our knowledge, this  
269 represents the first report from South Asia investigating the impact of PCVs on OM.



270

271 A key finding from our study is the 15.4% reduction in pneumococcal positivity among otorrhea  
272 cases over four years following the introduction of PCV10. This reduction is consistent with  
273 systematic analyses of studies evaluating the impact of PCV on OM, which have reported  
274 reductions ranging from 8% to 42.7% for PCV7, 5.6% to 84% for PCV10, and 2.2% to 68% for  
275 PCV13 [15]. Similar results were seen from studies in Vietnam, a southeast Asian country that  
276 introduced PCV10 in March 2017 and observed a ~40% reduction in pneumococcal OM cases  
277 [21].

278

279 Our data indicated a 44.1% reduction in VT OM cases, with significant decreases observed in  
280 most PCV10 serotypes, including 19F, 6B, and 14. Limited cross-protection was noted for  
281 serotype 6A, as reported in several studies [15,22]. In contrast, no significant difference was  
282 noted for serotype 1 and low case numbers precluded effective estimates for serotypes 4, 5, and  
283 7F. As expected, PCV10 had no effect on non-vaccine-type (NVT) OM cases. An increase in  
284 certain NVT serotype's such as 35B was observed, along with a rise in the number of serotypes  
285 post-vaccination, frequency of NVT OM cases did not change through the study period. These  
286 changes in serotype distribution did not result in differences in median age, ear discharge  
287 duration, or the antimicrobial susceptibility against five commonly used antibiotics.

288

289 An interesting trend was observed with serotype 19A, which became an increasingly common  
290 cause of invasive pneumococcal disease in some countries following the introduction of PCVs  
291 that did not include the 19A antigen [23,24]. Some studies suggested that the 19F antigen  
292 included in PCV10 could offer cross-protection for 19A [8]. Initially, we observed a reduction

293 in the proportion of 19A cases for two years post-vaccination. Genomic sequencing of isolates  
294 could offer an understanding of the changes in the observed phenotype [25].

295  
296 Using indirect cohort analysis, the vaccine efficacy of PCV10 against VT pneumococcal OM  
297 cases was calculated at 84.4%, aligning with efficacy observed in other settings, in both  
298 developed and developing countries [15,21]. We also evaluated the coverage of other  
299 pneumococcal vaccines, noting coverage rates of 41.7% for Serum Institute PCV10, 53.5% for  
300 PCV13, 54.4% for PCV15, and 64.5% for PCV20. Incorporating PCV15 or PCV20 could  
301 potentially increase the proportion of OM cases preventable by vaccination, suggesting a benefit  
302 from higher valent pneumococcal vaccines in enhancing disease coverage.

303  
304 Several limitations should be considered when interpreting our results. First, tympanocentesis  
305 was not performed on children without otorrhea, which may have led to lack of detection of  
306 certain pathogens. However, since 94% of the suspected OM cases presented with otorrhea, this  
307 limitation likely had minimal, if any, impact on our analysis. Plus, the possibility of missing  
308 bacterial pathogens in this study was low as we used selective and enriched (nonselective) media  
309 specifically for pneumococcus and *H. influenzae*. Second, we did not test for viral pathogen in  
310 the specimens, which may also play a role as co-pathogens in OM cases. Third, the study was  
311 conducted at the outpatient department of a single hospital in Dhaka, the capital city of  
312 Bangladesh. It is likely that severe OM cases, especially those with draining ears, are more  
313 inclined to seek care at facilities like Bangladesh Shishu Hospital and Institute, which is  
314 equipped to handle more complex conditions. Conversely, milder cases of OM are often  
315 managed in private clinics or pharmacies. Therefore, the impact of PCV10 observed in this study

316 might not fully represent its effect across different healthcare settings and regions within  
317 Bangladesh.—Moreover, having only one year of pre-PCV data limited our ability to discern  
318 longer-term trends in serotype distribution pre- and post-vaccination. Finally, the lack of a  
319 population-based denominator in our surveillance data precludes incidence calculations.

320

321 Despite these limitations, our study provides robust evidence of the significant impact of PCV10  
322 on pneumococcal OM cases due to vaccine serotypes in Bangladesh. Studies that detail OM  
323 outcomes by specific pneumococcal serotypes are exceedingly rare, making our data particularly  
324 valuable to the existing literature. This serotype-specific analysis offers a critical perspective on  
325 vaccine effects, especially given the high burden of OM. In the absence of population-based  
326 studies, the large number of cases identified through our hospital-based surveillance enabled a  
327 detailed examination of PCV10's impact in Bangladesh. This study underscores the value of  
328 serotype-specific investigations in understanding and enhancing vaccine effectiveness in  
329 preventing serious health outcomes. Collectively, these findings underscore the importance of  
330 continued support for PCV vaccination, highlighting its positive impact on the overall well-being  
331 of children not only in Bangladesh but across the region.

332

### 333 **AUTHOR CONTRIBUTION**

334 SKS conceived the study, provided supervision, and secured funding. HN, MHR, ShS, MI  
335 conducted the laboratory tests. SKS, MH and MJA supervised the sample collection. HN, RCD  
336 and YH performed the data analysis and generated the figures. YH, SS, HN and SKS wrote the  
337 manuscript. YH, SS, CJW and SKS reviewed the manuscript.

338

339 **FUNDING STATEMENT**

340 This work was supported by Pfizer Inc (Grant number: WI209075). The funding organization had  
341 no role in the design, implementation, data analysis, manuscript writing or decision to publish  
342 this study.

343

344 **CONFLICT OF INTEREST**


345 Authors declare no conflict of interest.

## 346 REFERENCES

- 347 [1] Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of  
348 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era  
349 of conjugate vaccines: global, regional, and national estimates for 2000–15. *The Lancet*  
350 *Global Health* 2018;6:e744–57. [https://doi.org/10.1016/S2214-109X\(18\)30247-X](https://doi.org/10.1016/S2214-109X(18)30247-X).
- 351 [2] Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, et al. Estimates of the  
352 global, regional, and national morbidity, mortality, and aetiologies of lower respiratory  
353 infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of  
354 Disease Study 2016. *The Lancet Infectious Diseases* 2018;18:1191–210.  
355 [https://doi.org/10.1016/S1473-3099\(18\)30310-4](https://doi.org/10.1016/S1473-3099(18)30310-4).
- 356 [3] Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. *Wkly*  
357 *Epidemiol Rec* 2007;82:93–104.
- 358 [4] Pneumococcal conjugate vaccines: WHO position paper n.d.  
359 <https://www.who.int/publications-detail-redirect/10665-310968> (accessed April 1, 2024).
- 360 [5] Malaker R, Hasanuzzaman M, Hooda Y, Rahman H, Chandra Das R, Kanon N, et al.  
361 Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal  
362 disease among children <2 years old: A prospective population-based study in rural  
363 Bangladesh. *Vaccine* 2024;42:255–62. <https://doi.org/10.1016/j.vaccine.2023.12.007>.
- 364 [6] Saha S, Hasan M, Kim L, Farrar JL, Hossain B, Islam M, et al. Epidemiology and risk  
365 factors for pneumonia severity and mortality in Bangladeshi children <5 years of age before  
366 10-valent pneumococcal conjugate vaccine introduction. *BMC Public Health* 2016;16:1233.  
367 <https://doi.org/10.1186/s12889-016-3897-9>.
- 368 [7] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in  
369 invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate  
370 vaccine. *N Engl J Med* 2003;348:1737–46. <https://doi.org/10.1056/NEJMoa022823>.
- 371 [8] Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any  
372 cross-protection against serotype 19A? *BMC Pediatr* 2010;10:4.  
373 <https://doi.org/10.1186/1471-2431-10-4>.
- 374 [9] DGHS Health Bulletin n.d. [https://old.dghs.gov.bd/index.php/en/publications/health-](https://old.dghs.gov.bd/index.php/en/publications/health-bulletin/dghs-health-bulletin)  
375 [bulletin/dghs-health-bulletin](https://old.dghs.gov.bd/index.php/en/publications/health-bulletin/dghs-health-bulletin) (accessed April 1, 2024).
- 376 [10] McCollum ED, Ahmed S, Roy AD, Chowdhury NH, Schuh HB, Rizvi SJR, et al.  
377 Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic  
378 pneumonia among children in rural Bangladesh: A case-control study. *Vaccine*  
379 2020;38:6508–16. <https://doi.org/10.1016/j.vaccine.2020.08.035>.
- 380 [11] Monasta L, Ronfani L, Marchetti F, Montico M, Brumatti LV, Bavcar A, et al. Burden of  
381 Disease Caused by Otitis Media: Systematic Review and Global Estimates. *PLOS ONE*  
382 2012;7:e36226. <https://doi.org/10.1371/journal.pone.0036226>.
- 383 [12] Jin Y, Yang X, Sun H, Zhang J, Yang S, Jiang S, et al. Global, Regional, and National  
384 Burdens of Otitis Media From 1990 to 2019: A Population Based Study. *Ear and Hearing*  
385 n.d.:10.1097/AUD.0000000000001453. <https://doi.org/10.1097/AUD.0000000000001453>.
- 386 [13] O'Neill P, Roberts T, Bradley Stevenson C. Otitis media in children (acute). *BMJ Clin Evid*  
387 2007;2007:0301.
- 388 [14] Naziat H, Saha S, Islam M, Saha S, Uddin MJ, Hussain M, et al. Epidemiology of Otitis  
389 Media With Otorrhea Among Bangladeshi Children: Baseline Study for Future Assessment

- 390 of Pneumococcal Conjugate Vaccine Impact. *The Pediatric Infectious Disease Journal*  
391 2018;37:715. <https://doi.org/10.1097/INF.0000000000002077>.
- 392 [15] Sévaux JL de, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, et al.  
393 Pneumococcal conjugate vaccines for preventing acute otitis media in children. *Cochrane*  
394 *Database of Systematic Reviews* 2020. <https://doi.org/10.1002/14651858.CD001480.pub6>.
- 395 [16] Rosario DC, Mendez MD. *Chronic Suppurative Otitis*. StatPearls, Treasure Island (FL):  
396 StatPearls Publishing; 2024.
- 397 [17] Grevers G, Wiedemann S, Bohn J-C, Blasius R-W, Harder T, Kroeniger W, et al.  
398 Identification and characterization of the bacterial etiology of clinically problematic acute  
399 otitis media after tympanocentesis or spontaneous otorrhea in German children. *BMC Infect*  
400 *Dis* 2012;12:312. <https://doi.org/10.1186/1471-2334-12-312>.
- 401 [18] Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al.  
402 Comparison of Antibiotic Resistance and Serotype Composition of Carriage and Invasive  
403 Pneumococci among Bangladeshi Children: Implications for Treatment Policy and Vaccine  
404 Formulation. *Journal of Clinical Microbiology* 2003;41:5582–7.  
405 <https://doi.org/10.1128/JCM.41.12.5582-5587.2003>.
- 406 [19] Jorgensen JH, Howell AW, Maher LA. Quantitative antimicrobial susceptibility testing of  
407 *Haemophilus influenzae* and *Streptococcus pneumoniae* by using the E-test. *J Clin*  
408 *Microbiol* 1991;29:109–14. <https://doi.org/10.1128/jcm.29.1.109-114.1991>.
- 409 [20] Bar-Zeev N, Swarouth TD, Everett DB, Alaerts M, Msefula J, Brown C, et al. Impact and  
410 effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of  
411 vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi,  
412 2006–18: prospective observational time-series and case-control studies. *The Lancet Global*  
413 *Health* 2021;9:e989–98. [https://doi.org/10.1016/S2214-109X\(21\)00165-0](https://doi.org/10.1016/S2214-109X(21)00165-0).
- 414 [21] Toizumi M, Satoh C, Quilty BJ, Nguyen HAT, Madaniyazi L, Le LT, et al. Effect of  
415 pneumococcal conjugate vaccine on prevalence of otitis media with effusion among  
416 children in Vietnam. *Vaccine* 2022;40:5366–75.  
417 <https://doi.org/10.1016/j.vaccine.2022.07.047>.
- 418 [22] Eskola Juhani, Kilpi Terhi, Palmu Arto, Jokinen Jukka, Eerola Mervi, Haapakoski Jaason,  
419 et al. Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. *New*  
420 *England Journal of Medicine* 2001;344:403–9.  
421 <https://doi.org/10.1056/NEJM200102083440602>.
- 422 [23] Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a  
423 multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. *J*  
424 *Antimicrob Chemother* 2009;64:507–10. <https://doi.org/10.1093/jac/dkp210>.
- 425 [24] Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal  
426 Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–2011.  
427 *Emerg Infect Dis* 2013;19:1074–83. <https://doi.org/10.3201/eid1907.121830>.
- 428 [25] Nakano S, Fujisawa T, Chang B, Ito Y, Akeda H, Fujita J, et al. Whole-Genome Analysis-  
429 Based Phylogeographic Investigation of *Streptococcus pneumoniae* Serotype 19A Sequence  
430 Type 320 Isolates in Japan. *Antimicrob Agents Chemother* 2022;66:e0139521.  
431 <https://doi.org/10.1128/AAC.01395-21>.
- 432


433 **SUPPLEMENTARY FIGURES**



434


435 **Sup Figure 1:** Yearly distribution of OM cases attributable to *S. pneumoniae* serotypes not  
436 covered by PCVs from April 2014 to March 2019.

437



438

439 **Sup Figure 2:** Age distribution of OM cases attributable to *S. pneumoniae* during the study  
440 period.



441

442 **Sup Figure 3:** Ear discharge of OM cases attributable to *S. pneumoniae* during the study period.

443

444

445 **Sup Table 1:** List of all bacterial pathogens isolated from otitis media episodes detected at

446 Bangladesh Shishu Hospital and Institute during the study period: April 2015 – March 2019

447 (N=3735).

Bacterial pathogen detected	Number
<i>Haemophilus influenzae</i>	418
<i>Streptococcus pneumoniae</i>	292
<i>Staphylococcus aureus</i>	308
<i>Pseudomonas spp</i>	286
<i>Acinetobacter spp</i>	43
<i>Proteus mirabilis</i>	16
<i>Klebsiella pneumoniae</i>	47
<i>Aeromonas hydrophila</i>	1
<i>Escherichia coli</i>	38
<i>Streptococcus pyogenes</i>	101
<i>Enterobacter spp</i>	27
<i>Serratia spp</i>	6
<i>Candida</i>	15
<i>Citrobacter spp</i>	4



<i>Morganella Morganii</i>	4
<i>Streptococcus agalactiae</i>	6
<i>Klebsiella oxytoca</i>	3
<i>Proteus vulgaris</i>	8
<i>Providencia spp</i>	4
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i>	171
<i>Streptococcus pneumoniae</i> + <i>Streptococcus pyogenes</i>	1
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i>	32
<i>Streptococcus pneumoniae</i> + <i>Pseudomonas spp</i>	14
<i>Streptococcus pneumoniae</i> + <i>Acinitobacter spp</i>	3
<i>Streptococcus pneumoniae</i> + <i>Klebsiella pneumoniae</i>	7
<i>Streptococcus pneumoniae</i> + <i>Escherichia coli</i>	5
<i>Streptococcus pneumoniae</i> + <i>Enterobacter spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Providencia spp</i>	3
<i>Streptococcus pneumoniae</i> + <i>Candida</i>	1
<i>Streptococcus pneumoniae</i> + <i>Proteus mirabilis</i>	4
<i>Streptococcus pneumoniae</i> + <i>Moraxella catarrhalis</i>	1
<i>Haemophilus influenzae</i> + <i>Staphylococcus aureus</i>	78
<i>Haemophilus influenzae</i> + <i>Streptococcus agalactiae</i>	1
<i>Haemophilus influenzae</i> + <i>Moraxella catarrhalis</i>	1
<i>Haemophilus influenzae</i> + <i>Pseudomonas spp</i>	12
<i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i>	20
<i>Haemophilus influenzae</i> + <i>Enterobacter spp</i>	6
<i>Haemophilus influenzae</i> + <i>Acinitobacter spp</i>	3
<i>Haemophilus influenzae</i> + <i>Klebsiella pneumoniae</i>	7
<i>Haemophilus influenzae</i> + <i>Escherichia coli</i>	6
<i>Haemophilus influenzae</i> + <i>Providencia spp</i>	1
<i>Haemophilus influenzae</i> + <i>Proteus mirabilis</i>	1
<i>Haemophilus influenzae</i> + <i>Streptococcus spp</i>	1
<i>Haemophilus influenzae</i> + <i>Candida</i>	1
<i>Streptococcus pyogenes</i> + <i>Acinitobacter spp</i>	1
<i>Streptococcus pyogenes</i> + <i>Klebsiella pneumoniae</i>	2
<i>Streptococcus pyogenes</i> + <i>Enterobacter spp</i>	2
<i>Streptococcus pyogenes</i> + <i>Staphylococcus aureus</i>	15
<i>Streptococcus pyogenes</i> + <i>Pseudomonas spp</i>	7
<i>Moraxella catarrhalis</i> + <i>Acinitobacter spp</i>	1
<i>Moraxella catarrhalis</i> + <i>Pseudomonas spp</i>	1
<i>Staphylococcus aureus</i> + <i>Pseudomonas spp</i>	12
<i>Staphylococcus aureus</i> + <i>Escherichia coli</i>	9

<i>Staphylococcus aureus</i> + <i>Acinetobacter spp</i>	6
<i>Staphylococcus aureus</i> + <i>Enterobacter spp</i>	10
<i>Staphylococcus aureus</i> + <i>Klebsiella pneumoniae</i>	8
<i>Staphylococcus aureus</i> + <i>Providencia spp</i>	1
<i>Staphylococcus aureus</i> + <i>Serratia spp</i>	1
<i>Staphylococcus aureus</i> + <i>Klebsiella oxytoca</i>	1
<i>Klebsiella pneumoniae</i> + <i>Escherichia coli</i>	5
<i>Klebsiella pneumoniae</i> + <i>Enterobacter spp</i>	2
<i>Klebsiella pneumoniae</i> + <i>Pseudomonas spp</i>	10
<i>Klebsiella oxytoca</i> + <i>Pseudomonas spp</i>	1
<i>E. coli</i> + <i>Pseudomonas spp</i>	2
<i>Enterobacter spp</i> + <i>Pseudomonas spp</i>	2
<i>Proteus mirabilis</i> + <i>Pseudomonas spp</i>	4
<i>Proteus mirabilis</i> + <i>Serratia spp</i>	1
<i>Acinitibacter sp</i> + <i>Pseudomonas spp</i>	1
<i>Acinitibacter sp</i> + <i>Citobacter spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Acinitobacter spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Klebsiella pneumoniae</i>	1
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Escherichia coli</i>	2
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Enterobacter spp</i>	2
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Providencia spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Staphylococcus aureus</i>	23
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Pseudomonas spp</i>	3
<i>Streptococcus pneumoniae</i> + <i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i>	3
<i>Streptococcus pneumoniae</i> + <i>Streptococcus pyogenes</i> + <i>Pseudomonas spp</i>	2
<i>Streptococcus pneumoniae</i> + <i>Proteus vulgaris</i> + <i>Pseudomonas spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Klebsiella pneumoniae</i> + <i>Pseudomonas spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i> + <i>Acinitobacter spp</i>	2
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i> + <i>Klebsiella pneumoniae</i>	1
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i> + <i>Enterobacter spp</i>	1
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i> + <i>Proteus mirabilis</i>	1
<i>Streptococcus pneumoniae</i> + <i>Staphylococcus aureus</i> + <i>Pseudomonas spp</i>	1
<i>Haemophilus influenzae</i> + <i>Staphylococcus aureus</i> + <i>Escherichia coli</i>	1
<i>Haemophilus influenzae</i> + <i>Staphylococcus aureus</i> + <i>Acinitobacter spp</i>	2
<i>Haemophilus influenzae</i> + <i>Pseudomonas spp</i> + <i>Acinitobacter spp</i>	1
<i>Haemophilus influenzae</i> + <i>Pseudomonas spp</i> + <i>Escherichia coli</i>	1
<i>Haemophilus influenzae</i> + <i>Klebsiella pneumoniae</i> + <i>Acinitobacter spp</i>	2
<i>Haemophilus influenzae</i> + <i>Klebsiella pneumoniae</i> + <i>Enterobacter spp</i>	1
<i>Haemophilus influenzae</i> + <i>Klebsiella pneumoniae</i> + <i>Escherichia coli</i>	1

<i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i> + <i>Acinitobacter spp</i>	1
<i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i> + <i>Klebsiella pneumoniae</i>	1
<i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i> + <i>Staphylococcus aureus</i>	5
<i>Haemophilus influenzae</i> + <i>Streptococcus pyogenes</i> + <i>Streptococcus agalactiae</i>	1
<i>Haemophilus influenzae</i> + <i>Staphylococcus aureus</i> + <i>Pseudomonas spp</i>	2
<i>Streptococcus pyogenes</i> + <i>Staphylococcus aureus</i> + <i>Pseudomonas spp</i>	1
<i>Streptococcus pyogenes</i> + <i>Staphylococcus aureus</i> + <i>Acinitobacter spp</i>	1
No bacterial pathogen detected	1554
<b>Total</b>	<b>3735</b>

448